Quest Diagnostics Incorporated (DGX) — RQD Stock Rating Cockpit
Quest Diagnostics Incorporated (DGX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Real cash coming in backs up reported profits (33% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on DGX
10.3% ROIC with 33.2% gross margin and 4.88% FCF yield.
Altman-Z 4.01 and Piotroski 8/9 pass balance-sheet audit.
Put/Call 0.78x with 22/40 institutional & insider flow.
- ✓Strong cash generator (33% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live DGX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
DGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DGX. Explore sector supply chains on /butterfly.
DGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell DGX stock right now?
Quest Diagnostics Incorporated (DGX) currently earns a Roarable Rating of C+ (Hold — HOLD) with 67/100 RQD Confidence. Solid 33% profit margin (10% return on capital), mixed timing at 28x P/E—hold if owned, no rush to chase.
What is DGX's 12-month price target and RQD AI Jury consensus?
DGX's 12-month base price target is $263.16 (range $205.26 to $310.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.